相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Yun Fan et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
Dongxu Wang et al.
FRONTIERS IN ONCOLOGY (2021)
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Lu Xie et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
Jieqiong Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee et al.
LANCET ONCOLOGY (2020)
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
Guosheng Yuan et al.
ONCOTARGETS AND THERAPY (2020)
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack et al.
FRONTIERS IN IMMUNOLOGY (2020)
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte et al.
CELL (2019)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Sha Zhao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Omar Khan et al.
NATURE (2019)
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers
Chang Gon Kim et al.
SCIENCE IMMUNOLOGY (2019)
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
Effect of Apatinib on Serum CD4+CD25+T cells, NK Cells, and T Cells Subgroup in Malignant Tumor
Hui-Qin Luo et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2019)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
Jin Li et al.
BMC CANCER (2010)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
